NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon has filed to raise up to $125 million in an initial public offering.

The Germantown, Md.-based firm has not yet determined a price range on its shares, and it didn't disclose in its Form S-1 filed with the US Securities Exchange on Tuesday how many shares it plans to offer. JP Morgan and Barclays will be joint book-running managers on the offering.

Intrexon plans to list on the New York Stock Exchange under ticker symbol "XON".

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.